Polymer 3D printing and additive manufacturing solutions provider Stratasys Ltd. (NASDAQ: SSYS) announced on Monday that it is collaborating with healthcare technology company Siemens Healthineers in a pioneering research project to advance medical imaging phantoms for computed tomography (CT) imaging.
CT phantoms, crucial in medical imaging, simulate human body characteristics to evaluate CT scanner performance. The joint project uses Stratasys' PolyJet technology and RadioMatrix technology, along with Siemens Healthineers' advanced algorithm, aiming to create tailored phantoms with ultra-realistic human anatomy characteristics.
This collaboration may revolutionise medical phantom utilisation, potentially replacing human cadavers with 3D printed structures, providing efficiencies and minimising human variability.
The research will produce valuable data for advancing CT system algorithms, materials development and unlocking new application areas. The phased project starts with 3D printed phantoms for head and neck anatomies, leading to a Phase One endpoint of 3D printing a heart model and an entire human torso with complete radiographic accuracy.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline